CellPoint and Lonza Enter Strategic Collaboration to Deliver CAR-T Cells to Patients at Point-of-Care
CellPoint and Lonza will utilize Lonza's CocoonPlatformin combination with CellPoint's online xCellit Platform for workflow managementto manufacture cell therapies at the point-of-care.
- CellPoint and Lonza will utilize Lonza's CocoonPlatformin combination with CellPoint's online xCellit Platform for workflow managementto manufacture cell therapies at the point-of-care.
- Tol Trimborn, Chief Executive Officer of CellPoint, said: "CellPoint's T-cell therapies have enormous potential for treating various cancers.
- Eytan Abraham, Head of Lonza Personalized Medicine, commented: "We look forward to collaborating with CellPoint to enable and accelerate bringing novel cancer immunotherapies to the clinic and patients.
- CellPoint is a Dutch (EU) company founded to provide affordable and readily available CAR-T therapies for all patients in need.